Chairs: Harry Janssen and Raymond Schinazi

• 3:10 p.m. - 3:30 p.m. Universal Standards for new HBV biomarkers to improve their utility - Jordan Feld
• 3:30 p.m. - 3:40 p.m. Evidence for durable HBsAg declines after long-term CAM therapies - Tse-I Lin
• 3:40 p.m. - 3:50 p.m. RNA interference with ASO: Is functional cure sustained long-term?
• 3:50 p.m. - 4:00 p.m. RNA interference with ASO: Latest results from new kid on the block
• 4:00 p.m. - 4:10 p.m. Bulevirtide + IFN-α in long-term treated HDV patients: optimal duration for sustained responses - Amos Lichtman
• 4:10 p.m. - 4:25 p.m. Gene and epigenomic editing: early results in 3 elevator pitches
• 4:25 p.m. - 4:55 p.m. Discussion